Fidelity Investments’s Metagenomi Therapeutics MGX Stock Holding History

Fidelity Investments’s Portfolio MGX Stock Details MGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.32K	Sell	4,718 -2,090	-31%	-$3.25K	﹤0.01%	4867
2025 Q4	$11K	Sell	6,808 -3,388	-33%	-$7.33K	﹤0.01%	4696
2025 Q3	$24.2K	Buy	10,196 +369	+4%	+$749	﹤0.01%	4282
2025 Q2	$14.5K	Sell	9,827 -4,022	-29%	-$6.3K	﹤0.01%	4400
2025 Q1	$18.8K	Buy	13,849 +5,216	+60%	+$12.4K	﹤0.01%	4248
2024 Q4	$31.2K	Buy	8,633 +4,114	+91%	+$9.93K	﹤0.01%	4053
2024 Q3	$9.81K	Buy	+4,519	New	+$15.7K	﹤0.01%	4433

Other funds holding MGX

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

CCM

Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return

PLC

Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PVI

Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments's MGX Position: Q1 2026 in Review

Fidelity Investments reduced its Metagenomi Therapeutics (MGX) stake by 31% in Q1 2026, selling an estimated $3.25K and leaving 4,718 shares worth $6.32K. The position accounts for ﹤0.01% of the portfolio, ranked #4867.

Fidelity Investments first reported a position in MGX in Q3 2024 and has held it in 7 quarters since. The position peaked at $31.2K in Q4 2024. 48 funds tracked by Wall St. Rank hold MGX as of Q1 2026.

Fidelity Investments held 4,718 shares of Metagenomi Therapeutics worth $6.32K as of Q1 2026.
Fidelity Investments sold 2,090 Metagenomi Therapeutics shares in Q1 2026, an estimated $3.25K.
Metagenomi Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #4867 holding.
Fidelity Investments first reported a position in Metagenomi Therapeutics in Q3 2024 and has held it in 7 quarters since.
Fidelity Investments's Metagenomi Therapeutics position peaked at $31.2K in Q4 2024.
48 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.